ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR

DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent successful transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis.

ACC 2022 | ADAPT-TAVR: Endoxaban No Better Than DAPT After TAVI

This study included 229 patients whose mean age was 80 years; 42% of them were male. Patients were randomized to either endoxaban 60 mg or 30 mg every 24 h or dual antiplatelet therapy (DAPT, aspirin plus clopidogrel).

Low dosage was used in 61.3% of patients because they met one of the following criteria: moderate to severe function impairment, low weight, or concomitant use of P-glycoprotein inhibitors. After 6 months, they were tested by means of 4-dimensional angioTAC, neurological and cognitive assessment, and brain MRI.

Populations were similar, with no difference in characteristics between groups, and 90% received a balloon-expandable valve. The Society of Thoracic Surgeons (STS) score was 3.3%.

After 6 months of follow-up, endoxaban failed to show a significant difference in fewer leafleat thrombosis in the intent-to-treat arm, but there was a difference in patients with high DOAC compliance (9.1% vs. 19.1%; hazard ratio [HR]: 0.48; 95% confidence interval [CI]: 0.23-0.99).

Read also: ACC 2022 | BENTRACIMAB.

There were no differences in the secondary endpoints, which included leaflet mobility reduction ≥3; presence, number and volume of new brain lesions in the MRI; and neurological changes.

Leaflet hypoattenuation was not linked to new brain lesions, neurological disorders, or cognitive disfunction.

Furthermore, there were no differences in the safety endpoints, which included death, stroke, systemic thromboembolism, or bleeding vs. DAPT (11.7% vs. 12.7%; HR: 0.93; 95% CI: 0.44-1.96).

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org .


Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

More articles by this author

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...